Research programme: checkpoint inhibitors - OSE Immunotherapeutics

Drug Profile

Research programme: checkpoint inhibitors - OSE Immunotherapeutics

Alternative Names: Effi dem; OSE-172

Latest Information Update: 30 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Effimune
  • Developer OSE Immunotherapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Checkpoint kinase inhibitors; Immunomodulators; SIRPA protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 26 Sep 2017 OSE Immunotherapeutics extends its agreement with Selexis for clinical development of OSE 172
  • 26 Sep 2017 OSE Immunotherapeutics plans to initiate phase I/II clinical trial of OSE 172 in Cancer in 2018
  • 15 Nov 2016 Selexis SA and OSE Immunotherapeutics collaborate to advance preclinical development of OSE 172
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top